Nicholas Grund insider trades: Akebia Therapeutics (AKBA) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Nicholas reports to the SEC
Open-market buys and sales
2 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Feb 2, 2026 | AKBA | ↓ Sell10b5-1 | 84,829 | $1.39 | $118K | Direct | Feb 4, 2026 (2d) |
| Feb 3, 2025 | AKBA | ↓ Sell10b5-1 | 55,621 | $2.10 | $117K | Direct | Feb 4, 2025 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other AKBA insiders
Open-market trades in the last 12 months
About Nicholas Grund's insider trades
Nicholas Grund is Chief Commercial Officer at Akebia Therapeutics (AKBA). Since Feb 3, 2025, Nicholas has reported no open-market purchases and 2 sales worth $235K on SEC Form 4. In the last 12 months: 1 sale ($118K).
2 sales (100% of the value sold) were made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so they say little about how the insider sees the stock today.
Their filings also include grants and awards (7 filings), shares withheld for taxes (5 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every AKBA insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.